CXCL10 and neoplasm: To assess the functional impact of CXCL10, the use of an in-vivo neutralizing antibody against CXCR3 revealed that CXCR3 neutralization attenuated the tumor control efficacy of the MEKi and RT combination therapy, as evidenced by increased tumor volume and weight (Figures 1G–I).